Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 24, 2013 08:07 ET | Source: Argos Therapeutics

Argos Therapeutics Announces Globalization of Pivotal Phase 3 ADAPT Study for Personalized Cancer Immunotherapy

DURHAM, N.C., Sept. 24, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
September 16, 2013 08:07 ET | Source: Argos Therapeutics

JAIDS Study by Argos Therapeutics Evaluates Impact of Personalized Immunotherapy in HIV-Infected Patients

DURHAM, N.C., Sept. 16, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
September 06, 2013 09:45 ET | Source: Argos Therapeutics

Argos Therapeutics to Present at the Stifel Healthcare Conference 2013

DURHAM, N.C., Sept. 6, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
August 27, 2013 08:00 ET | Source: Argos Therapeutics

Argos Therapeutics Secures $42.5 Million Financing, Funds Pivotal Phase 3 ADAPT Trial for Personalized Immunotherapy

DURHAM, N.C., Aug. 27, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
August 15, 2013 08:03 ET | Source: Argos Therapeutics

Argos Therapeutics Identifies Topical Formulation for Prolonged Graft Survival in Corneal Transplants

DURHAM, N.C., Aug. 15, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of therapies that modulate the immune system to...
July 01, 2013 15:03 ET | Source: Argos Therapeutics

Argos Therapeutics Announces Plans for HIV Eradication Study

DURHAM, N.C., July 1, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
June 13, 2013 09:59 ET | Source: Argos Therapeutics

Leading HIV Researchers and Argos Therapeutics Highlight Importance of Immunotherapy in HIV Eradication Efforts

DURHAM, N.C., June 13, 2013 (GLOBE NEWSWIRE) -- In conjunction with the U.S. Food and Drug Administration's (FDA) June 14th Public Meeting on HIV Patient-Focused Drug Development and HIV Cure...
June 10, 2013 11:03 ET | Source: Argos Therapeutics

Argos Therapeutics Announces US and Global Expansion for Ongoing Pivotal Phase 3 ADAPT Study for Personalized Immunotherapy

DURHAM, N.C., June 10, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
May 20, 2013 08:05 ET | Source: Argos Therapeutics

Argos Therapeutics to Present at the Sachs Cancer Bio Partnering Forum

DURHAM, N.C., May 20, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
April 29, 2013 09:01 ET | Source: Argos Therapeutics

Argos Therapeutics to Present at the 12th Annual Needham Healthcare Conference

DURHAM, N.C., April 29, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...